# A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

> **NCT01617460** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 86 (actual)

## Conditions studied

- Autistic Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01617460
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617460, "A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01617460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*